At the news
? BULLISHIMPACT 8/10 8-K filed Apr 15, 2026 at 08:55 ET
PDS Biotechnology announced positive interim Phase 2 clinical trial data for its drug PDS01ADC in treating metastatic colorectal cancer, showing a 78% objective response rate and 85% 2-year survival rate compared to 35% in a parallel trial.
- PDS01ADC showed 77.8% objective response rate (ORR) at 6 months vs 35% in parallel trial
- 24-month survival rate was approximately 85% vs 40% in parallel trial
- Data published in Journal of Clinical Oncology (JCO) Oncology Advances
- Trial conducted in unresectable microsatellite stable (MSS) or mismatch repair-proficient p(MMR) colorectal liver metastases
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access